SRDX241220C20000
- 0.00
- 0.000.00%
SurModics Newsroom
SurModics Inc. Faces Legal Hurdles: Shareholder Lawsuits Threaten Merger and Financial Stability
SurModics | 10-K: FY2024 Annual Report
Express News | CORRECTION: Surmodics Reported Q4 Financial Results on Nov. 6
SurModics (SRDX) Is an Incredible Growth Stock: 3 Reasons Why
Barrington Maintains SurModics(SRDX.US) With Hold Rating
Hold Rating Maintained for SurModics Amid Acquisition Uncertainty
Surmodics Analyst Ratings
Needham Maintains SurModics(SRDX.US) With Hold Rating
Needham Sticks to Their Hold Rating for SurModics (SRDX)
Surmodics Reports Q4 EPS (13c), Consensus (29c)
Express News | Surmodics Inc: Co Is Not Introducing Financial Guidance for Fiscal 2025 in Light of Pending Acquisition by Gtcr
Express News | Surmodics Inc: Qtrly Total Rev $33.2 Mln
Earnings Flash (SRDX) SURMODICS Posts Q4 Revenue $33.2M
SurModics | 8-K: Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Express News | Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Express News | Surmodics Q4 Net Income USD -3.449 Million
Press Release: Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Surmodics 4Q Loss $3.45M >SRDX
Surmodics Announces Early Subset Analysis Of 60 Patients With Acute, Subacute, Or Chronic Symptoms Of Limb Ischemia Demonstrated 96.8% Procedural Flow Restoration, With 81.7% Of Subjects Not Receiving Additional Thromboemboli Removal Treatment Post...
Surmodics Announces Early Results From PROWL Registry Study of Real-World Limb Ischemia Patients Treated With Pounce Thrombectomy System